The mental healthcare system is in desperate need of innovation.
By harnessing the enormous potential of rapid acting psychedelics and digital technology we aim to deliver psychedelic therapies to all those who need them — where and when they need them.
An atai Life Sciences company
Viridia Life Sciences is a biotech company dedicated to developing N,N-Dimethyltryptamine in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.
This pragmatic approach to simplifying DMT administration and the in-clinic treatment paradigm will help people access not only the neurogenic benefits of DMT, but also the personal insights that can accompany psychedelic-assisted psychotherapy… The impact for patients and their families may be transformative.
- Glenn Short
, CEO, Viridia Life Sciences
Meet Viridia, the ATAI unit exploring ayahuasca-based treatments for mental illness
Can ayahuasca, a psychoactive brew used traditionally in South America, be used to treat depression and other mental illnesses? Biotech builder ATAI Life Sciences is setting up a subsidiary to find out: Viridia Life Sciences.
July 22, 2020
ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews
Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences.
July 22, 2020